Shares of Avinger, Inc. (NASDAQ:AVGR) fell -3.65% to reach at $0.44 during previous trading session. The company has experienced volume of 252,613 shares while on average the company has a capacity of trading 4.63M share.
Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), recently declared it has reached an exclusive distribution agreement with Integmed Ltd. for the sales and marketing of Avinger’s Lumivascular products in Hong Kong. Initial product shipments are anticipated during the current quarter and first patient treatments in Hong Kong are expected to begin in the third quarter of 2019.
Integmed is a leading distributor of medical devices in Hong Kong for the treatment of cardiovascular disease, counting a portfolio of complementary products for the endovascular treatment of arterial disease.
“We are excited to enter the Hong Kong market through our new distribution relationship with Integmed, a highly regarded distributor with directly relevant clinical experience,” said Jeff Soinski, Avinger’s President and CEO. “PAD is a global health problem that affects over 200 million people worldwide and is a leading cause of atherosclerotic vascular morbidity. By expanding availability of our proprietary Lumivascular products to new geographic markets, we can provide important new clinical tools for physicians to safely and effectively treat their patients.
We believe that our partnership with Integmed will enable a positive impact on the treatment of peripheral arterial disease in Hong Kong and support the growth of our business as we expand to new markets.”
Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger’s proprietary Lightbox console.
Physicians performing atherectomy with other devices must rely solely on X-ray as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which presently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices.
Avinger, Inc. (NASDAQ:AVGR) holds the market capitalization of $29.63M along with 64.69M outstanding shares. During the last trade, stock’s minimum price has been reached out at $0.44 while the maximum trading price moved at $0.46. Currently the stock price is moving 145.17% off from the highest level of twelve months and -78.26% above from twelve months low. Avinger, Inc. (NASDAQ:AVGR) marked 52-week highest price level of $2.03 on May 2, 2018 and 52-week lowest price level of $0.18 on May 7, 2018.
As of current trade, Avinger, Inc. (NASDAQ:AVGR) has shown weekly downbeat performance of -7.29%. Its six months performance indicated a bullish 36.68% movement while its yearly performance reflected a negative trend of -74.56%. Year-to-date (YTD) performance of the stock illustrate upbeat trend of 52.67%. Shares of Avinger, Inc. (NASDAQ:AVGR) currently have an ABR of 1.00, derived from a total of 1 opinions. The company’s price sits -26.46% below from its 50-day moving average of $0.5370 and -34.06% below from the stock’s 200-day moving average of $0.5138. The company has Relative Strength Index (RSI 14) of 37.68 along with Average True Range (ATR 14) of 0.05. Its weekly and monthly volatility is 8.96%, 8.08% respectively. The company’s beta value is at 1.83.
Avinger, Inc. currently has a PEG ratio of 0 where as its P/E ratio is 0. The company’s price to sales ratio for trailing twelve months is 3.75 and price to book ratio for most recent quarter is 1.48, whereas price to cash per share for the most recent quarter is 1.77. Avinger, Inc. (NASDAQ:AVGR)’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 1.60 along with current ratio for most recent quarter of 1.90. Total debt to equity ratio of the company for most recent quarter is 0.59 whereas long term debt to equity ratio for most recent quarter is 0.00. Avinger, Inc. (NASDAQ:AVGR) has a Return on Assets of -117.70%. The company currently has a Return on Equity of -307.30% and Return on Investment of 0.